Jaakkola S, Salmikangas P, Nylund S, Partanen J, Armstrong E, Pyrhönen S, Lehtovirta P, Nevanlinna H
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Finland.
Int J Cancer. 1993 May 28;54(3):378-82. doi: 10.1002/ijc.2910540305.
We have investigated gene amplification of fibroblast growth factor receptor-4 (FGFR4) gene in 30 primary breast tumor samples and 15 gynecological tumor samples. Ten percent of the breast tumors showed 2- to 4-fold amplification. Amplification was found more frequently in estrogen- and progesterone-receptor-positive tumors and in tumors with high lymph-node involvement. Breast tumor samples were also analyzed for the amplification of fgfr3 and erbB2 genes and the chromosome 11q13 located genes hst1/int2/bcl1/sea. erbB2 gene was amplified 2- to 13-fold in 13% of the cases, but no amplification of int2/hst1/bcl1/sea amplicon was found. Gynecological tumors were also analyzed for the amplification of fgfr4 and fgfr3 genes and for int2 and hst1 oncogenes. Eleven of the 15 gynecological tumors were ovarian neoplasms including 2 benign tumors; the remainder comprised 1 ovarian metastasis of breast cancer; 1 endometrial cancer; 1 uterine leiomyosarcoma and 1 carcinosarcoma of the fallopian tube. In gynecological tumors, fgfr4 gene was found to be amplified in 2 ovarian tumors. Amplification of hst1 was found in 1 benign ovarian tumor. Thus, the fgfr4 gene may be involved in breast and ovarian tumorigenesis.
我们对30份原发性乳腺肿瘤样本和15份妇科肿瘤样本中的成纤维细胞生长因子受体4(FGFR4)基因进行了基因扩增研究。10%的乳腺肿瘤显示出2至4倍的扩增。扩增在雌激素和孕激素受体阳性肿瘤以及高淋巴结受累的肿瘤中更为常见。还对乳腺肿瘤样本进行了fgfr3和erbB2基因以及位于11q13染色体上的hst1/int2/bcl1/sea基因的扩增分析。13%的病例中erbB2基因扩增了2至13倍,但未发现int2/hst1/bcl1/sea扩增子的扩增。对妇科肿瘤也进行了fgfr4和fgfr3基因以及int2和hst1癌基因的扩增分析。15份妇科肿瘤中有11份是卵巢肿瘤,包括2份良性肿瘤;其余包括1份乳腺癌卵巢转移瘤、1份子宫内膜癌、1份子宫平滑肌肉瘤和1份输卵管癌肉瘤。在妇科肿瘤中,发现2份卵巢肿瘤中有fgfr4基因扩增。在1份良性卵巢肿瘤中发现了hst1的扩增。因此,fgfr4基因可能参与乳腺和卵巢肿瘤的发生。